Effect of Carvedilole compared to Terazosin plus Enalapril in treatment of Hypertension and benign prostatic hyperplasia

Effect of Carvedilole and combination of Terazosin plus Enalapril on blood pressure and urinary symptoms among patients with Hypertension and Benign Prostatic Hyperplasia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181128041777N1

Enrollment

Registered

2019-03-14

Start date

2018-12-22

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Hypertension. Condition 2: Benign prostate hyperplasia. Essential (primary) hypertension Enlarged prostate with lower urinary tract symptoms

Interventions

Intervention 1: Intervention group 1: After random allocation in 2 groups, first group was treated with Carvedilol, produced by SOHA company, 12.5 mg (Max 25 mg) and Blood pressure was kept in normal

Eligibility

Sex/Gender

Male

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: Moderate hypertension (according European guide line blood pressure between 140-159 in systolic and 90-99 in diastolic) Men above 40 years with benign prostatic hyperplasia that diagnosis with permanent LUTS during the last 6 months ,physical examination, ultrasonography and serum PSA

Exclusion criteria

Exclusion criteria: History of using alfa blockers during the last 6 months history of uncontrolled or malignant urgency HTN history of using anti hypertensive and prostate drugs history of prostate cancer history of prostate surgery

Design outcomes

Primary

Measure	Time frame
Q max: Maximum urinary flow rate show in uroflowmetry. Timepoint: in 4 time: before treatment. after carvedilol. before enalapril and terazosin and after that. Method of measurement: uroflowmetry.	—

Secondary

Measure	Time frame
PVR :Post Voiding Residual. Timepoint: in 4 time: before treatment. after carvedilol. before enalapril and terazosin and after that. Method of measurement: Sonography.;IPSS : international prostate symptom score. Timepoint: in 4 time: before treatment. after carvedilol. before enalapril and terazosin and after that. Method of measurement: International prostate symptom score questionnaire.;PSA : prostate specific antigen. Timepoint: in 4 time: before treatment. after carvedilol. before enalapril and terazosin and after that. Method of measurement: Blood test.;Systolic blood pressure. Timepoint: in 4 time: before treatment. after carvedilol. before enalapril and terazosin and after that. Method of measurement: mercury manometer.;Diastolic blood pressure. Timepoint: in 4 time: before treatment. after carvedilol. before enalapril and terazosin and after that. Method of measurement: mercury manometer.	—

Measure

Time frame

PVR :Post Voiding Residual. Timepoint: in 4 time: before treatment. after carvedilol. before enalapril and terazosin and after that. Method of measurement: Sonography.;IPSS : international prostate symptom score. Timepoint: in 4 time: before treatment. after carvedilol. before enalapril and terazosin and after that. Method of measurement: International prostate symptom score questionnaire.;PSA : prostate specific antigen. Timepoint: in 4 time: before treatment. after carvedilol. before enalapril and terazosin and after that. Method of measurement: Blood test.;Systolic blood pressure. Timepoint: in 4 time: before treatment. after carvedilol. before enalapril and terazosin and after that. Method of measurement: mercury manometer.;Diastolic blood pressure. Timepoint: in 4 time: before treatment. after carvedilol. before enalapril and terazosin and after that. Method of measurement: mercury manometer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNooriyeh Dalir Akbari

Tabriz University of Medical Sciences

info@imamreza.tbzmed.ac.ir+98 41 3335 9633

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026